TXMD News and Press, TherapeuticsMD Inc. From 05/24/21

BOCA RATON, Fla.--(BUSINESS WIRE)--May 24, 2021-- TherapeuticsMD, Inc. (NASDAQ: TXMD), has been awarded a Top Workplaces 2021 honor by The Sun Sentinel. The list is based solely on employee feedback gathered through a third-party survey administered by employee engagement technology partner En...

Therapeutics MD (TXMD): Q1 GAAP EPS of -$0.58 misses by $0.47.Cash, cash equivalents, and investments of $333.3M.The company projects net cash use of $100-110 million for 2021, which includes tenant improvements to the Rockville facility and  expects cash on hand to support ope...

The following slide deck was published by TherapeuticsMD, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: TherapeuticsMD, Inc. 2021 Q1 - Results - Earnings Call Presentation

Image source: The Motley Fool. TherapeuticsMD, Inc. (NASDAQ: TXMD) Q1 2021 Earnings Call May 06, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: TherapeuticsMD, Inc. (TXMD) Q1 2021 Earnings Call Transcript

TherapeuticsMD, Inc. (TXMD) Q1 2021 Earnings Conference Call May 06, 2021, 08:30 AM ET Company Participants Nichol Ochsner - Vice President of Investor Relations Rob Finizio - Chief Executive Officer James D'Arecca - Chief Financial Officer Dawn Halkuff - Chief Commercial Officer Mitchell Kra...

James River Group Holdings (JRVR) -23% after stock offering and Q1 earnings release.Fastly (FSLY) -19% on Q1 earnings release.Regional Health Properties (RHE) -15%.Rocket Companies (RKT) -13% on Q1 earnings release.Etsy (ETSY) -11% on Q1 earnings releas...

TherapeuticsMD (TXMD) reports financial results for the first quarter ended March 31, 2021.Total revenue for Q1 increased 62% to $19.87M compared to Q1 2020. Analysts forecast was $19.77M.ANNOVERA net product revenue increased by $6.5M to $8.8M vs. $2.3M in prior year.IMVEXXY revenue increase...

- 1Q21 total net revenue increased to $19.9 million - - 1Q21 total net product revenue increased 60% to $19.6 million compared to 1Q20 - - ANNOVERA prescriptions continue to grow with increasing consumer support and acceptance - - Further strengthened ANNOVERA® patent f...

Executive Management to Host Conference Call on May 6, 2021 at 8:30 a.m. ET TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it will report its first quarter 2021 financial results on Thursday, May 6, 2021, before the ope...

Although sales grew by 30% in the fourth quarter, the market remains disinterested. ANNOVERA remains the key. Management are bullish on what is to come without restrictions in a post-covid world. The market remains concerned about dilution, negative earnings, and negative equity. ...